@misc{oai:repo.qst.go.jp:00073220,
 author = {佐原, 成彦 and 佐原 成彦},
 month = {Sep},
 note = {Abstract
Accumulation of intracellular neurofibrillary tangles (NFTs) consisting of microtubule-associated protein tau is a major hallmark of Alzheimer’s disease (AD) and related neurodegenerative diseases regarded as ‘tauopathies’ (1-3). Findings of tau gene mutations in FTDP-17-tau families have provided direct evidence that tau abnormalities alone can induce neurodegenerative disorders (4-6). Therefore, visualization of tau accumulation would offer a reliable, objective indicator to diagnose of tauopathy and to assess the disease progression. Positron emission tomography (PET) imaging of tau lesions is currently available using several tau PET ligands including [11C]PBB3 [reviewed in (7)]. However, more compelling in vivo and neuropathological evidence supporting binding of PBB3 to tau lesions in diverse tauopathies (e.g., AD, Progressive supranuclear palsy, Corticobasal degeneration, Argyrophilic grain disease, Pick’s disease) is still required since the presence of tau pathologies in scanned subjects has not been confirmed in the aforementioned clinical PET assay. PBB3 is a fluorescent compound, and is accordingly supposed to be useful for multimodal imaging studies, potentially allowing us to validate its binding to diverse tau inclusions (e.g., NFTs, globus NFTs, astrocytic plaques, tufted astrocytes, coiled bodies, Pick bodies, and ballooned neurons) by histological methods (8). Here, I will present our progress of pathological characteristics of PBB3 binding on tau lesions in brains of human subjects with various tauopathies and tau transgenic mice. Moreover, ongoing studies will be introduced for the usefulness of tau PET ligands in the early detection of tauopathies., 2nd International Conference on Alzheimer”s Disease & Dementian},
 title = {Tau PET imaging: New insight into early diagnosis of tauopathy},
 year = {2014}
}